MCM4

DNA replication licensing factor MCM4 · P33991 · MCM4 on Sugi Atlas →

488 patent compounds predicted against MCM4, 425 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Alisertib (SCHEMBL855823)	1.00	1/20
Alisertib (SCHEMBL29354333)	1.00	1/20
Alisertib (SCHEMBL29437869)	1.00	1/20
Alisertib (SCHEMBL29720486)	1.00	1/20
Alisertib (SCHEMBL29750414)	1.00	1/20
Alisertib (SCHEMBL854553)	0.98	1/20
Alisertib (SCHEMBL15263514)	0.98	1/20
Alisertib (SCHEMBL14125416)	0.97	1/20
SCHEMBL2389378	0.94	1/20
SCHEMBL2389355	0.89	1/20
SCHEMBL2392579	0.89	1/20
SCHEMBL20214913	0.89	1/20
SCHEMBL12454978	0.89	1/20
SCHEMBL26005084	0.89	1/20
SCHEMBL2386771	0.87	1/20
Alisertib (SCHEMBL854552)	0.86	1/20
Alisertib (SCHEMBL29664627)	0.86	1/20
Alisertib (SCHEMBL30405892)	0.86	1/20
SCHEMBL12054412	0.86	1/20
SCHEMBL10072296	0.86	1/20

Clinical trials — most relevant to MCM4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt	PHASE4	COMPLETED
Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment	PHASE2/PHASE3	RECRUITING
Intracameral Antibiotic Safety Study	PHASE3	SUSPENDED
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer	PHASE1/PHASE2	COMPLETED
BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors	PHASE2	WITHDRAWN
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies	PHASE1/PHASE2	RECRUITING
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)	PHASE1/PHASE2	RECRUITING
M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers	PHASE1/PHASE2	COMPLETED
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)	PHASE1/PHASE2	NOT_YET_RECRUITING
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer	PHASE2	UNKNOWN
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers	PHASE1/PHASE2	COMPLETED
A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects	PHASE1/PHASE2	COMPLETED
Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor	PHASE1/PHASE2	NOT_YET_RECRUITING
Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts	PHASE1	ACTIVE_NOT_RECRUITING
Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma	PHASE1	WITHDRAWN
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
Plasma Triglyceride Lipolysis in Multifactorial Chylomicronemia	nan	COMPLETED
Profiles of Expression in HPV+ Versus HPV Head and Neck Cancers	nan	UNKNOWN
Role of Geminin and Mcm-2 in Prognosis of Renal Cell Carcinoma	nan	UNKNOWN
Telomeres Length in Israeli Fibrotic ILD Patients	nan	ENROLLING_BY_INVITATION
A Clinical Evaluation of Everolimus Eluting Coronary Stents in the Treatment of Patients With ST-segment Elevation Myocardial Infarction: EXAMINATION Study	nan	COMPLETED
Study of the Effect of Innate on the Inflammatory Response to Endotoxin	nan	RECRUITING
Genetic Analysis of Familial Melanoma	nan	COMPLETED
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients	nan	COMPLETED
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients	nan	ACTIVE_NOT_RECRUITING
Body Awareness and Aerobic Exercise: Telomere Impact	nan	COMPLETED
Spironolactone and XPB-1 Integrity in the TFIIH Complex	nan	ENROLLING_BY_INVITATION

Related proteins — ESM-2 sequence neighbours (a MCM4 binder may also engage these)

Protein	Name	Similarity
P49717	—	1.000	P49717 →
Q6GL41	—	1.000	Q6GL41 →
Q26454	—	1.000	Q26454 →
Q5XK83	—	1.000	Q5XK83 →
P30664	—	1.000	P30664 →
Q9UJA3	—	0.995	Q9UJA3 →
Q95XQ8	—	0.993	Q95XQ8 →
I0IUP3	—	0.993	I0IUP3 →
Q5F310	—	0.992	Q5F310 →
D3ZVK1	—	0.991	D3ZVK1 →
Q9CWV1	—	0.991	Q9CWV1 →
Q0V9Q6	—	0.990	Q0V9Q6 →
P29458	—	0.988	P29458 →
Q5JKB0	—	0.988	Q5JKB0 →
E1BPX4	—	0.988	E1BPX4 →
Q9SF37	—	0.987	Q9SF37 →
Q9VUV9	—	0.985	Q9VUV9 →
Q9SYP1	—	0.985	Q9SYP1 →
NAT10	RNA cytidine acetyltransferase	0.984	landscape →
Q0WVF5	—	0.984	Q0WVF5 →
Q9U2G0	—	0.984	Q9U2G0 →
Q6F353	—	0.984	Q6F353 →
Q5ZMN2	—	0.983	Q5ZMN2 →
F4KAB8	—	0.983	F4KAB8 →
Q00578	—	0.982	Q00578 →
B8AZX3	—	0.982	B8AZX3 →
Q7ZXZ0	—	0.981	Q7ZXZ0 →
A4FUD9	—	0.981	A4FUD9 →
Q9VGW6	—	0.981	Q9VGW6 →
Q9UT24	—	0.981	Q9UT24 →